A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Durvalumab (Primary) ; MEDI 0562 (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 22 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 20 May 2017 Planned number of patients changed from 161 to 404.
- 20 May 2017 Planned End Date changed from 1 Sep 2023 to 21 Apr 2023.